Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.
Allan Lipton
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Karim Fizazi
Consultant or Advisory Role - Amgen
Alison Stopeck
Consultant or Advisory Role - Amgen; Genentech
Honoraria - Amgen
David H. Henry
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Matthew Raymond Smith
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Neal D. Shore
Consultant or Advisory Role - Amgen
Miguel Martin
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Amgen; GlaxoSmithKline
Saroj Vadhan-Raj
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Kefei Zhou
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Arun Balakumaran
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen